News & Press Releases

Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“ 

Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.

Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing. 

Mintz secured a rare trademark temporary restraining order (TRO) on behalf of IYO, Inc. against OpenAI, Sam Altman, Sir Jony Ive, and IO Products, Inc. The order temporarily bars the defendants from using the trademark associated with their new product launch. 

Michael T. Renaud, Chair of Mintz’s Intellectual Property Division, has been named to Bloomberg Law’s 2025 Unrivaled Litigators list. The inaugural award celebrates litigators at law firms and elsewhere who lead the legal industry in high-stakes trials and settlements on impactful matters for clients.

Mintz advised Brij—a software platform enhancing the consumer experience by bridging online and offline commerce—on the closing of its $8 million Series Seed round. The funding will help Brij advance its mission to close the trillion-dollar disconnect between brands and their retail customers and power the next generation of offline-to-online customer relationships.